AIC
BTAI icon

Ameritas Investment Company’s BioXcel Therapeutics BTAI Stock Holding History

Ameritas Investment Company’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1
Closed – – 485
2020
Q1 		$0 Buy
+1
New +$359 ﹤0.01% 1761
2019
Q4 		– Sell
-5
Closed -$1K – 928
2019
Q3 		$1K Buy
+5
New +$789 ﹤0.01% 1544

Other funds holding BTAI

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Ameritas Investment Company's BTAI Position: Q2 2020 in Review

Ameritas Investment Company sold out of BioXcel Therapeutics (BTAI) in Q2 2020, closing a stake of 1 share.

Ameritas Investment Company first reported a position in BTAI in Q3 2019 and held it in 2 quarters. The position peaked at $1K in Q3 2019. 104 funds tracked by Wall St. Rank hold BTAI as of Q2 2020.

  • Ameritas Investment Company reported no remaining BioXcel Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Ameritas Investment Company sold 1 BioXcel Therapeutics share in Q2 2020.
  • Ameritas Investment Company first reported a position in BioXcel Therapeutics in Q3 2019 and held it in 2 quarters.
  • Ameritas Investment Company's BioXcel Therapeutics position peaked at $1K in Q3 2019.
  • 104 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2020.

Based on Ameritas Investment Company's 13F filing for Q2 2020, filed 14 Aug 2020.